메뉴 건너뛰기




Volumn 15, Issue 2, 2016, Pages 165-171

Asthma and atopic dermatitis: A review of targeted inhibition of interleukin-4 and interleukin-13 as therapy for atopic disease

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; IL4 PROTEIN, HUMAN; INTERLEUKIN-13, HUMAN;

EID: 85016441988     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (20)

References (57)
  • 1
    • 80052028124 scopus 로고    scopus 로고
    • Treatment of allergic asthma: Modulation of Th2 cells and their responses
    • Bosnjak B, Stelzmueller B, Erb KJ, et al. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011;12:114-30.
    • (2011) Respir Res , vol.12 , pp. 114-130
    • Bosnjak, B.1    Stelzmueller, B.2    Erb, K.J.3
  • 2
    • 84873389433 scopus 로고    scopus 로고
    • A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
    • Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330-8.
    • (2013) Eur Respir J , vol.41 , pp. 330-338
    • Piper, E.1    Brightling, C.2    Niven, R.3
  • 3
    • 84908095090 scopus 로고    scopus 로고
    • Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
    • Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769-79.
    • (2014) J Allergy Clin Immunol , vol.134 , pp. 769-779
    • Leung, D.Y.1    Guttman-Yassky, E.2
  • 4
    • 84901826411 scopus 로고    scopus 로고
    • Advances in the diagnosis and therapeutic management of atopic dermatitis
    • Vestergaard C, Deleuran M. Advances in the diagnosis and therapeutic management of atopic dermatitis. Drugs. 2014;74:757-69.
    • (2014) Drugs , vol.74 , pp. 757-769
    • Vestergaard, C.1    Deleuran, M.2
  • 5
    • 84918564629 scopus 로고    scopus 로고
    • Therapeutic strategies in extrinsic atopic dermatitis: Focus on inhibition of IL-4 as a new pharmacological approach
    • Di Lernia V. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach. Expert Opin Ther Targets. 2015;19:87-96.
    • (2015) Expert Opin Ther Targets , vol.19 , pp. 87-96
    • Di Lernia, V.1
  • 6
    • 79951966004 scopus 로고    scopus 로고
    • Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life
    • Guilbert TW, Garris C, Jhingran P, et al. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma. 2011;48:126-32.
    • (2011) J Asthma , vol.48 , pp. 126-132
    • Guilbert, T.W.1    Garris, C.2    Jhingran, P.3
  • 7
    • 84922352134 scopus 로고    scopus 로고
    • The translational revolution and use of biologics in patients with inflammatory skin diseases
    • Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135:324-36.
    • (2015) J Allergy Clin Immunol , vol.135 , pp. 324-336
    • Noda, S.1    Krueger, J.G.2    Guttman-Yassky, E.3
  • 8
    • 84865085421 scopus 로고    scopus 로고
    • Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
    • Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venerol. 2012;26:1176-93.
    • (2012) J Eur Acad Dermatol Venerol , vol.26 , pp. 1176-1193
    • Ring, J.1    Alomar, A.2    Bieber, T.3
  • 9
    • 84879401471 scopus 로고    scopus 로고
    • Dupilumab in persistent asthma with elevated eosinophil levels
    • Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66.
    • (2013) N Engl J Med , vol.368 , pp. 2455-2466
    • Wenzel, S.1    Ford, L.2    Pearlman, D.3
  • 10
    • 0032522641 scopus 로고    scopus 로고
    • An antagonistic IL-4 mutant prevents type I allergy in the mouse: Inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo
    • Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol. 1998;160:4004-9.
    • (1998) J Immunol , vol.160 , pp. 4004-4009
    • Grunewald, S.M.1    Werthmann, A.2    Schnarr, B.3
  • 11
    • 0037841660 scopus 로고    scopus 로고
    • Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma
    • Hahn C, Teufel M, Herz U, et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol. 2003;111:1361-9.
    • (2003) J Allergy Clin Immunol , vol.111 , pp. 1361-1369
    • Hahn, C.1    Teufel, M.2    Herz, U.3
  • 12
    • 84939937146 scopus 로고    scopus 로고
    • New pathogenic and therapeutic paradigms in atopic dermatitis
    • Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73:311-18.
    • (2015) Cytokine , vol.73 , pp. 311-318
    • Malajian, D.1    Guttman-Yassky, E.2
  • 13
    • 49549108250 scopus 로고    scopus 로고
    • Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation
    • Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008;128:2248-58.
    • (2008) J Invest Dermatol , vol.128 , pp. 2248-2258
    • Howell, M.D.1    Fairchild, H.R.2    Kim, B.E.3
  • 14
    • 84873333462 scopus 로고    scopus 로고
    • The multifunctional role of filaggrin in allergic skin disease
    • McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131:280-91.
    • (2013) J Allergy Clin Immunol , vol.131 , pp. 280-291
    • McAleer, M.A.1    Irvine, A.D.2
  • 15
    • 80053517839 scopus 로고    scopus 로고
    • Filaggrin mutations associated with skin and allergic diseases
    • Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315-27.
    • (2011) N Engl J Med , vol.365 , pp. 1315-1327
    • Irvine, A.D.1    McLean, W.H.2    Leung, D.Y.3
  • 16
    • 16844386596 scopus 로고    scopus 로고
    • Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis
    • Hatano Y, Terashi H, Arakawa S, et al. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124:786-92.
    • (2005) J Invest Dermatol , vol.124 , pp. 786-792
    • Hatano, Y.1    Terashi, H.2    Arakawa, S.3
  • 17
    • 84903269864 scopus 로고    scopus 로고
    • The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products
    • Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014;71:177-84.
    • (2014) J Am Acad Dermatol , vol.71 , pp. 177-184
    • Meckfessel, M.H.1    Brandt, S.2
  • 19
    • 77951890216 scopus 로고    scopus 로고
    • IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation
    • Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-90.
    • (2010) J Immunol , vol.184 , pp. 3186-3190
    • Sehra, S.1    Yao, Y.2    Howell, M.D.3
  • 20
    • 3242798310 scopus 로고    scopus 로고
    • Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
    • Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752-60.
    • (2004) Nat Immunol , vol.5 , pp. 752-760
    • Dillon, S.R.1    Sprecher, C.2    Hammond, A.3
  • 21
    • 84857054959 scopus 로고    scopus 로고
    • IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis
    • Bao L, Shi VY, Chan LS. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis. Mol Immunol. 2012;50:91-7.
    • (2012) Mol Immunol , vol.50 , pp. 91-97
    • Bao, L.1    Shi, V.Y.2    Chan, L.S.3
  • 22
    • 84906255127 scopus 로고    scopus 로고
    • Biologic therapy in asthma: Entering the new age of personalized medicine
    • Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. J Asthma. 2014;51:669-76.
    • (2014) J Asthma , vol.51 , pp. 669-676
    • Fajt, M.L.1    Wenzel, S.E.2
  • 23
    • 80054117099 scopus 로고    scopus 로고
    • Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population
    • Namkung JH, Lee JE, Kim E, et al. Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population. Exp Dermatol. 2011;20:915-9.
    • (2011) Exp Dermatol , vol.20 , pp. 915-919
    • Namkung, J.H.1    Lee, J.E.2    Kim, E.3
  • 24
    • 0034973569 scopus 로고    scopus 로고
    • Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer
    • Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Gen. 2001;69:138-47.
    • (2001) Am J Hum Gen , vol.69 , pp. 138-147
    • Ritchie, M.D.1    Hahn, L.W.2    Roodi, N.3
  • 25
    • 4143122127 scopus 로고    scopus 로고
    • Gene-gene interaction between interleukin- 4 and interleukin-4 receptor alpha in Korean children with asthma
    • Lee SG, Kim BS, Kim JH, et al. Gene-gene interaction between interleukin- 4 and interleukin-4 receptor alpha in Korean children with asthma. Clin Exp Allergy. 2004;34:1202-8.
    • (2004) Clin Exp Allergy , vol.34 , pp. 1202-1208
    • Lee, S.G.1    Kim, B.S.2    Kim, J.H.3
  • 26
    • 77649198441 scopus 로고    scopus 로고
    • Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma
    • Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19:46-54.
    • (2010) Eur Respir Rev , vol.19 , pp. 46-54
    • Oh, C.K.1    Geba, G.P.2    Molfino, N.3
  • 27
    • 0029876629 scopus 로고    scopus 로고
    • Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
    • Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-9.
    • (1996) Immunity , vol.4 , pp. 313-319
    • Kaplan, M.H.1    Schindler, U.2    Smiley, S.T.3
  • 28
    • 30044449492 scopus 로고    scopus 로고
    • IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis
    • Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99-106.
    • (2006) Nat Med , vol.12 , pp. 99-106
    • Fichtner-Feigl, S.1    Strober, W.2    Kawakami, K.3
  • 29
    • 4344607622 scopus 로고    scopus 로고
    • Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma
    • Lee GR, Flavell RA. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol. 2004;16:1155-60.
    • (2004) Int Immunol , vol.16 , pp. 1155-1160
    • Lee, G.R.1    Flavell, R.A.2
  • 30
    • 52049123606 scopus 로고    scopus 로고
    • Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes
    • Nishi N, Yamamoto S, Ou W, et al. Enhanced CCL26 production by IL-4 through IFN-gamma-induced upregulation of type 1 IL-4 receptor in keratinocytes. Biochem Biophys Res Commun. 2008;376:234-40.
    • (2008) Biochem Biophys Res Commun , vol.376 , pp. 234-240
    • Nishi, N.1    Yamamoto, S.2    Ou, W.3
  • 31
    • 48349104562 scopus 로고    scopus 로고
    • Correlation of IL-31 serum levels with severity of atopic dermatitis
    • Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122:421-3.
    • (2008) J Allergy Clin Immunol , vol.122 , pp. 421-423
    • Raap, U.1    Wichmann, K.2    Bruder, M.3
  • 32
    • 59949089656 scopus 로고    scopus 로고
    • Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling
    • Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742-51.
    • (2009) J Invest Dermatol , vol.129 , pp. 742-751
    • Zheng, T.1    Oh, M.H.2    Oh, S.Y.3
  • 33
    • 10744227480 scopus 로고    scopus 로고
    • A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma
    • Nishikubo K, Murata Y, Tamaki S, et al. A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. Gene Ther. 2003;10:2119-25.
    • (2003) Gene Ther , vol.10 , pp. 2119-2125
    • Nishikubo, K.1    Murata, Y.2    Tamaki, S.3
  • 34
    • 0035340763 scopus 로고    scopus 로고
    • A murine IL-4 receptor antagonist that inhibits IL-4- And IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness
    • Tomkinson A, Duez C, Cieslewicz G, et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol. 2001;166:5792-800.
    • (2001) J Immunol , vol.166 , pp. 5792-5800
    • Tomkinson, A.1    Duez, C.2    Cieslewicz, G.3
  • 35
    • 34247522910 scopus 로고    scopus 로고
    • IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys
    • Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007;119:1251-7.
    • (2007) J Allergy Clin Immunol , vol.119 , pp. 1251-1257
    • Bree, A.1    Schlerman, F.J.2    Wadanoli, M.3
  • 36
    • 48049089594 scopus 로고    scopus 로고
    • YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models
    • Ohga K, Kuromitsu S, Takezawa R, et al. YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models. Eur J Pharmacol. 2008;590:409-16.
    • (2008) Eur J Pharmacol , vol.590 , pp. 409-416
    • Ohga, K.1    Kuromitsu, S.2    Takezawa, R.3
  • 37
    • 0031019987 scopus 로고    scopus 로고
    • A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction
    • Grunewald SM, Kunzmann S, Schnarr B, et al. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction. J Biol Chem. 1997;272:1480-3.
    • (1997) J Biol Chem , vol.272 , pp. 1480-1483
    • Grunewald, S.M.1    Kunzmann, S.2    Schnarr, B.3
  • 38
    • 77957764848 scopus 로고    scopus 로고
    • IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist
    • Slager RE, Hawkins GA, Ampleford EJ, et al. IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol. 2010;126:875-8.
    • (2010) J Allergy Clin Immunol , vol.126 , pp. 875-878
    • Slager, R.E.1    Hawkins, G.A.2    Ampleford, E.J.3
  • 39
    • 0034995872 scopus 로고    scopus 로고
    • Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
    • Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963-70.
    • (2001) J Allergy Clin Immunol , vol.107 , pp. 963-970
    • Borish, L.C.1    Nelson, H.S.2    Corren, J.3
  • 40
    • 0036379740 scopus 로고    scopus 로고
    • Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma
    • Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93-100.
    • (2002) Clin Exp Immunol , vol.130 , pp. 93-100
    • Hart, T.K.1    Blackburn, M.N.2    Brigham-Burke, M.3
  • 41
    • 80053084755 scopus 로고    scopus 로고
    • Lebrikizumab treatment in adults with asthma
    • Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
    • (2011) N Engl J Med , vol.365 , pp. 1088-1098
    • Corren, J.1    Lemanske, R.F.2    Hanania, N.A.3
  • 42
    • 84897379012 scopus 로고    scopus 로고
    • Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial
    • De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989-96.
    • (2014) J Allergy Clin Immunol , vol.133 , pp. 989-996
    • De Boever, E.H.1    Ashman, C.2    Cahn, A.P.3
  • 43
    • 69549129344 scopus 로고    scopus 로고
    • Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma
    • Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol. 2009;49:1025-36.
    • (2009) J Clin Pharmacol , vol.49 , pp. 1025-1036
    • Burmeister Getz, E.1    Fisher, D.M.2    Fuller, R.3
  • 44
    • 77953039047 scopus 로고    scopus 로고
    • A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma
    • Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788-96.
    • (2010) Am J Respir Crit Care Med , vol.181 , pp. 788-796
    • Corren, J.1    Busse, W.2    Meltzer, E.O.3
  • 45
    • 84903887689 scopus 로고    scopus 로고
    • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis
    • Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-9.
    • (2014) N Engl J Med , vol.371 , pp. 130-139
    • Beck, L.A.1    Thaci, D.2    Hamilton, J.D.3
  • 46
    • 84879352861 scopus 로고    scopus 로고
    • Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma
    • Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med. 2013;368:2511-3.
    • (2013) N Engl J Med , vol.368 , pp. 2511-2513
    • Wechsler, M.E.1
  • 47
    • 84864445917 scopus 로고    scopus 로고
    • IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist
    • Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012;130:516-22e4.
    • (2012) J Allergy Clin Immunol , vol.130
    • Slager, R.E.1    Otulana, B.A.2    Hawkins, G.A.3
  • 48
    • 0027451432 scopus 로고
    • Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation
    • Kruse N, Shen BJ, Arnold S, et al. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J. 1993;12:5121-9.
    • (1993) EMBO J , vol.12 , pp. 5121-5129
    • Kruse, N.1    Shen, B.J.2    Arnold, S.3
  • 49
    • 0027435159 scopus 로고
    • An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors
    • Aversa G, Punnonen J, Cocks BG, et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med. 1993;178:2213-8.
    • (1993) J Exp Med , vol.178 , pp. 2213-2218
    • Aversa, G.1    Punnonen, J.2    Cocks, B.G.3
  • 50
    • 0030950732 scopus 로고    scopus 로고
    • IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins
    • Schnarr B, Ezernieks J, Sebald W, et al. IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. Int Immunol. 1997;9:861-8.
    • (1997) Int Immunol , vol.9 , pp. 861-868
    • Schnarr, B.1    Ezernieks, J.2    Sebald, W.3
  • 51
    • 66149140228 scopus 로고    scopus 로고
    • IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis
    • Morioka T, Yamanaka K, Mori H, et al. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Brit J Dermatol. 2009;160:1172-9.
    • (2009) Brit J Dermatol , vol.160 , pp. 1172-1179
    • Morioka, T.1    Yamanaka, K.2    Mori, H.3
  • 52
    • 84876472759 scopus 로고    scopus 로고
    • Mutant interleukin-4/13 signaling blockade successfully suppresses acute phase inflammation
    • Nakanishi T, Yamanaka K, Kakeda M, et al. Mutant interleukin-4/13 signaling blockade successfully suppresses acute phase inflammation. Arch Dermatol Res. 2013;305:241-7.
    • (2013) Arch Dermatol Res , vol.305 , pp. 241-247
    • Nakanishi, T.1    Yamanaka, K.2    Kakeda, M.3
  • 53
    • 85029086430 scopus 로고    scopus 로고
    • Safety and efficacy of dupilumab versus placebo for moderate-to-severe atopic dermatitis in patients using topical corticosteroids (TCS): Greater efficacy observed with concomitant therapy compared to TCS alone
    • 3 March San Diego CA
    • Thaci D, Worm M, Ren H, et al. Safety and efficacy of dupilumab versus placebo for moderate-to-severe atopic dermatitis in patients using topical corticosteroids (TCS): Greater efficacy observed with concomitant therapy compared to TCS alone. Presented at: Annual Meeting, American Academy of Allergy, Asthma, and Immunology; 3 March 2014; San Diego, CA.
    • (2014) Annual Meeting, American Academy of Allergy, Asthma, and Immunology
    • Thaci, D.1    Worm, M.2    Ren, H.3
  • 54
    • 85029116278 scopus 로고    scopus 로고
    • Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A 12-week, Randomized, Double-Blind, Placebo-Controlled Study
    • 4 March San Diego CA
    • Bieber TRM. Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A 12-week, Randomized, Double-Blind, Placebo-Controlled Study. Presented at: Annual Meeting, American Academy of Allergy, Asthma, and Immunology; 4 March 2014; San Diego, CA.
    • (2014) Annual Meeting, American Academy of Allergy, Asthma, and Immunology
    • Bieber, T.R.M.1
  • 55
    • 84919635394 scopus 로고    scopus 로고
    • Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
    • Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293-300.
    • (2014) J Allergy Clin Immunol , vol.134 , pp. 1293-1300
    • Hamilton, J.D.1    Suarez-Farinas, M.2    Dhingra, N.3
  • 56
    • 84922387096 scopus 로고    scopus 로고
    • Targeted therapy for allergic diseases: At the intersection of cutting-edge science and clinical practice
    • Boguniewicz M, Leung DY. Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice. J Allergy Clin Immunol. 2015;135:354-6.
    • (2015) J Allergy Clin Immunol , vol.135 , pp. 354-356
    • Boguniewicz, M.1    Leung, D.Y.2
  • 57
    • 35348909044 scopus 로고    scopus 로고
    • Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies
    • Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422-31.
    • (2007) Lancet , vol.370 , pp. 1422-1431
    • Wenzel, S.1    Wilbraham, D.2    Fuller, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.